Samir Parekh, MD, on Surprising Efficacy of Sequential T-Cell Redirection Therapy in Multiple Myeloma


The director of translational research in myeloma at the Tisch Cancer Institute discussed the relevance of the new research as more CAR T therapies come to market.

“We do have some interesting correlative results from these patients, as they've gone through sequential therapies, that are quite eye popping and surprising even to scientists and immunologists alike at our institution. We also have a concurrent publication that should be coming out soon on what happens after CAR T progression and this is another important topic, especially as we have 2 approvedCAR Ts that are being used now in the US.”

New research out of Mount Sinai’s Tisch Cancer Institute published in Blood Advances has revealed that sequential use of different T cell redirection therapies, including chimeric antigen receptor (CAR) T-cell therapies, after relapsing on bispecific antibodies (BiAb) led to deep and durable responses in patients with relapsed/refractory multiple myeloma.

CGTLive spoke with Samir Parekh, MD, the director of translational research at the institute, to learn more about the surprising findings of the new study, including the preserved efficacy of secondary T-cell redirection therapies further down the line and not just as a next-line therapy. He discussed the relevance of the research as more CAR T-cell therapies are approved and come to the market.

Mouhieddine TH, Oekelen OV, Melnekoff DT, et al. Sequencing T-cell redirection therapies leads to deep and durable responses in relapsed/refractory myeloma patients. Blood Adv. Published online August 2, 2022. doi: 10.1182/bloodadvances.2022007923
Related Videos
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Jennifer Taylor-Cousar, MD, MSCS, on Early Signals of Efficacy With Cystic Fibrosis Gene Therapy
Leigh Ramos-Platt, MD, on Looking Forward to Gene Therapy’s Growth
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Manali Kamdar, MD, on Evaluating Liso-Cel in Mantle Cell Lymphoma by Lines of Therapy, Prior BTKi
Ignacio Mata, PhD, an associate professor of neurology at the Cleveland Clinic Lerner Institute
Subhash Tripathi, PhD, on Developing Safe, Specific Engineered Treg Cell Therapy
© 2024 MJH Life Sciences

All rights reserved.